Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Open-label Extension for Infantile Spasms
NCT02954887Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of cannabidiol in infantile epileptic spasms syndrome (IESS), sponsored by Jazz Pharmaceuticals plc. Started May 2017; status: completed.
02
Drugs
cannabidiol
03
Conditions
infantile epileptic spasms syndrome (IESS)
Beyond the preview
Go deeper on NCT02954887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954887.